AstraZeneca CEO Pascal Soriot [via AP]
August 9, 2019 06:36 AM EDTUpdated 04:46 PM
R&D
Pharma

As­traZeneca's flag­ship Tagris­so helps lung can­cer pa­tients live longer in piv­otal study

Natalie Grover

Reporter

As­traZeneca is off to a good start in Au­gust. Af­ter its PARP in­hibitor Lyn­parza scored in a prostate can­cer tri­al ear­li­er this week, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times